Emerald Advisers’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
– Sell
-485,954
Closed -$25.4M – 271
2018
Q3
$25.4M Sell
485,954
-20,470
-4% -$1.12M 0.93% 32
2018
Q2
$22M Sell
506,424
-195,975
-28% -$8.4M 0.83% 48
2018
Q1
$26M Sell
702,399
-19,039
-3% -$508K 1.04% 28
2017
Q4
$14.3M Sell
721,438
-6,995
-1% -$150K 0.55% 72
2017
Q3
$18.1M Buy
728,433
+17,977
+3% +$332K 0.74% 56
2017
Q2
$12.4M Buy
+710,456
New +$12.4M 0.52% 80

Other funds holding GTHX

Emerald Advisers's GTHX Position: Q4 2018 in Review

Emerald Advisers sold out of G1 Therapeutics (GTHX) in Q4 2018, closing a stake of 485,954 shares — an estimated $25.4M sold.

Emerald Advisers first reported a position in GTHX in Q2 2017 and held it in 6 quarters. The position peaked at $26M in Q1 2018. 93 funds tracked by Wall St. Rank hold GTHX as of Q4 2018.

  • Emerald Advisers reported no remaining G1 Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Emerald Advisers sold 485,954 G1 Therapeutics shares in Q4 2018, an estimated $25.4M.
  • Emerald Advisers first reported a position in G1 Therapeutics in Q2 2017 and held it in 6 quarters.
  • Emerald Advisers's G1 Therapeutics position peaked at $26M in Q1 2018.
  • 93 funds tracked by Wall St. Rank held G1 Therapeutics as of Q4 2018.

Based on Emerald Advisers's 13F filing for Q4 2018, filed 30 Jan 2019.